The Inflammatory Chemokine CCL5 and Cancer Progression
Top Cited Papers
Open Access
- 2 January 2014
- journal article
- review article
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2014, 1-12
- https://doi.org/10.1155/2014/292376
Abstract
Until recently, inflammatory chemokines were viewed mainly as indispensable “gate keepers” of immunity and inflammation. However, updated research indicates that cancer cells subvert the normal chemokine system and these molecules and their receptors become important constituents of the tumor microenvironment with very different ways to exert tumor-promoting roles. The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. This review summarizes updated information on the role of CCL5 and its receptor CCR5 in cancer cell proliferation, metastasis, and the formation of an immunosuppressive microenvironment and highlights the development of newer therapeutic strategies aimed to inhibit the binding of CCL5 to CCR5, to inhibit CCL5 secretion, or to inhibit the interactions among tumor cells and the microenvironment leading to CCL5 secretion.Keywords
Funding Information
- Ministero della Salute
This publication has 105 references indexed in Scilit:
- The Chemokine Superfamily RevisitedImmunity, 2012
- The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and ChemokinesCancer Microenvironment, 2011
- CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal CarcinomaPLOS ONE, 2011
- Chemokines in health and diseaseExperimental Cell Research, 2011
- Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasisCarcinogenesis: Integrative Cancer Research, 2011
- IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretionBritish Journal of Haematology, 2010
- Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agentsBioorganic & Medicinal Chemistry Letters, 2010
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escapeThe Journal of Pathology, 2010
- The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways1PLOS ONE, 2009
- Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactionsInternational Journal of Cancer, 2007